FDA clears AI tool for detecting undiagnosed heart valve disease in ECGs

FDA clears AI tool for detecting undiagnosed heart valve disease in ECGs

<p>The new software from Chicago-based Tempus AI was designed to identify signs of moderate or severe MR. This is the company's second FDA clearance in the last two months.</p>

Tempus AI wins FDA clearance for ECG-MR

ECG-MR is cleared to flag possible valve disease in at-risk patients 65 and older, while Tempus's Sept. 28 release gave no rollout date.